CurrentCignaPolicy N/A

Familial Chylomicronemia Syndrome - Tryngolza Prior Authorization Policy

Prior authorization policy describing medical necessity criteria, documentation and specialist prescribing requirements for coverage of Tryngolza for adults with familial chylomicronemia syndrome (FCS) under Cigna benefit plans.

Policy Summary

PayerCigna

PolicyFamilial Chylomicronemia Syndrome - Tryngolza Prior Authorization Policy

Policy CodePolicy N/A

Change TypeClarified/revised clinical criteria and prescriber specialty

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization and document baseline fasting triglyceride ≥ 880 mg/dL (measured before triglyceride‑lowering medications), diagnostic confirmation, and specialist prescriber information.

SourceLink

POLICY UPDATE CHANGES

The requirement regarding a fasting triglyceride level ≥ 880 mg/dL was clarified to state at baseline.

The requirement for a familial chylomicronemia score ≥ 10 was clarified to state Moulin familial chylomicronemia score.

Diagnostic requirement was separated into genetic testing, diagnosis by a validated scoring tool, or a clinical diagnosis.

Specialist prescriber requirement updated to include lipidologist and specifies cardiologist, endocrinologist, lipidologist, or physician focusing on severe hypertriglyceridemia.

≥ 880 mg/dLminimum baseline fasting triglyceride for approval

≥ 18minimum patient age for FDA‑approved indication

1 yearinitial approval duration

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Tryngolza (olezarsen)

Initial Therapy — FDA‑Approved Indication

Covered when ALL of the following are met:

Age: Patient is ≥ 18 years of age≥ 18 years

Triglyceride level: Patient has a fasting triglyceride level ≥ 880 mg/dL at baseline≥ 880 mg/dL

Baseline refers to measurement prior to treatment with triglyceride‑lowering medications (documentation required)

Diagnostic confirmation

Genetic testing: Molecular genetic test results demonstrate biallelic pathogenic variants in at least one gene causing familial chylomicronemia syndrome (examples: LPL, GPIHBP1, APOA5, APOC2, LMF1)
Documentation required
Inconclusive genetic test with validated score: Molecular genetic test results are inconclusive AND the patient has ONE of: (a) Moulin familial chylomicronemia syndrome score ≥ 10 OR (b) North American familial chylomicronemia syndrome score ≥ 45Moulin ≥ 10 or NAFCS ≥ 45
Documentation required
Clinical diagnosis
- Clinical history: History of acute pancreatitis not caused by alcohol or cholelithiasis OR history of recurrent hospitalizations for severe abdominal pain without other explainable cause
- Exclude secondary causes: Absence of secondary hypertriglyceridemia (e.g., obesity, uncontrolled diabetes)
- Treatment response: Lack of response to traditional triglyceride‑lowering medications (examples: statins, niacin, fibrates, omega‑3 fatty acids)

Concomitant management: Medication will be used concomitantly with a low‑fat diet

Low‑fat diet recommended as ≤ 20 grams of fat per day for adults (recommended)

Prescriber specialty: Medication is prescribed by a cardiologist, endocrinologist, lipidologist, or a physician who focuses in the treatment of disorders related to severe hypertriglyceridemia

Initial approval requires specialist involvement

Approval duration: If all criteria are met, approve for 1 year1 year

Prior authorization is recommended; documentation must be provided

Tryngolza (olezarsen) is not medically necessary for treatment of hypertriglyceridemia when there is no confirmed diagnosis of familial chylomicronemia syndrome (FCS). The policy explicitly excludes use for hypertriglyceridemia in the absence of confirmed FCS and may deny coverage for such indications.

Any use of Tryngolza other than the FDA‑approved indication for familial chylomicronemia syndrome is considered not medically necessary. Examples include treatment of hypertriglyceridemia without a confirmed diagnosis of FCS; although trials have evaluated Tryngolza in patients with moderate hypertriglyceridemia or severe hypertriglyceridemia and elevated cardiovascular risk, these are not FDA‑approved indications.

Coding and Key Clinical Thresholds

Drug codes (NDC)NDC

NDC not listed

Tryngolza (olezarsen) subcutaneous injection - specific NDC(s) not provided in document

Baseline fasting triglyceride

Baseline fasting triglyceride threshold≥ 880 mg/dL

Context in trial entry criteriaA fasting triglyceride level ≥ 880 mg/dL was required for Phase III trial enrollment

Documentation noteDocumentation must show fasting triglyceride ≥ 880 mg/dL at baseline

Provider Actions, Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior Authorization Required: Prior authorization is required for Tryngolza. Initial approvals are granted for up to 1 year and are contingent on meeting the policy criteria and submission of the required documentation. Tryngolza must be prescribed by or in consultation with a specialist (cardiologist, endocrinologist, lipidologist, or physician who focuses on severe hypertriglyceridemia).

Approval duration: 1 year
Prescriber requirement: cardiologist, endocrinologist, lipidologist, or specialist in severe hypertriglyceridemia

Prior Authorization

Concomitant Therapy and Prior Treatment

Concomitant therapy and prior treatment: A baseline fasting triglyceride must be documented prior to initiation and specifically prior to treatment with any triglyceride‑lowering medication. The patient must be using Tryngolza concomitantly with a low‑fat diet. The patient must have demonstrated lack of response to traditional triglyceride‑lowering medications (examples: statins, niacin, fibrates, omega‑3 fatty acids) when required by the clinical criteria (e.g., when diagnosis pathway requires lack of response).

Baseline fasting triglyceride measured prior to triglyceride‑lowering medication

Definitions and Scoring

Baseline (for triglyceride measurement)

Definition of baseline (measurement timing)Baseline refers to the fasting triglyceride measurement taken prior to treatment with triglyceride‑lowering medications

Examples of triglyceride‑lowering medicationsIncludes statins, niacin, fibrates, and omega‑3 fatty acids

Policy implicationBaseline value is required for coverage determination and must be documented in records

Moulin FCS score

What it isA validated familial chylomicronemia syndrome (FCS) scoring tool used as an alternative diagnostic pathway when genetic testing is inconclusive or unavailable

Threshold for likely FCSA Moulin FCS score ≥ 10 suggests FCS is very likely

Background

Familial chylomicronemia syndrome (FCS) is an ultrarare, genetic disorder characterized by severe, lifelong elevations in triglycerides due to biallelic pathogenic variants in genes such as LPL, GPIHBP1, APOA5, APOC2, or LMF1. Patients frequently present with triglyceride levels in the thousands and complications that include recurrent acute pancreatitis, eruptive xanthomas, and lipemia retinalis. The condition is estimated to affect approximately 1 to 10 per 1,000,000 persons in the United States. Tryngolza (olezarsen) is an apolipoprotein C‑III–directed antisense oligonucleotide indicated as an adjunct to a low‑fat diet to reduce triglycerides in adults with FCS.

Documentation Required

Required Documentation

Required documentation: Submit patient-specific chart notes and supporting records that demonstrate all required coverage criteria have been met. Documentation should include baseline fasting triglyceride value (≥ 880 mg/dL where applicable), results of molecular genetic testing or documented FCS scoring (Moulin score ≥ 10 or North American FCS score ≥ 45) or clinical diagnostic documentation (including history of acute or recurrent pancreatitis or hospitalizations and exclusion of secondary causes), evidence of prior triglyceride‑lowering medication trials and response, documentation of concomitant low‑fat diet counseling, and prescriber specialty. Acceptable documentation includes chart notes, lab reports, genetic test results, claims records, and prescription receipts. All documentation must include patient identifiers.

Baseline fasting triglyceride lab report (document value and date)
Molecular genetic test results OR Moulin/North American FCS score documentation OR clinical diagnostic notes meeting the listed criteria
Records of prior triglyceride‑lowering medication trials and response (statins, niacin, fibrates, omega‑3 fatty acids)
Documentation of low‑fat diet counseling and plan
Prescriber specialty and consultation notes
All documents must include patient-specific identifying information